InspireMD (NYSE:NSPR) Director Scott Ward Acquires 73,255 Shares

InspireMD, Inc. (NYSE:NSPR) Director Scott Ward purchased 73,255 shares of InspireMD stock in a transaction dated Thursday, May 7th. The stock was acquired at an average price of $1.15 per share, with a total value of $84,243.25. Following the acquisition, the director owned 237,096 shares in the company, valued at approximately $272,660.40. This represents a 44.71% increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link.

InspireMD Trading Down 0.9%

Shares of NSPR traded down $0.01 during mid-day trading on Friday, hitting $1.15. The company’s stock had a trading volume of 261,553 shares, compared to its average volume of 174,764. The company’s 50-day moving average is $1.51 and its 200-day moving average is $1.75. InspireMD, Inc. has a 52-week low of $1.02 and a 52-week high of $2.93. The firm has a market capitalization of $53.93 million, a price-to-earnings ratio of -1.53 and a beta of 0.82.

Institutional Inflows and Outflows

Several institutional investors have recently made changes to their positions in NSPR. Creative Planning purchased a new position in InspireMD in the second quarter valued at $44,000. Raymond James Financial Inc. increased its holdings in InspireMD by 28.9% in the second quarter. Raymond James Financial Inc. now owns 44,604 shares of the company’s stock valued at $101,000 after buying an additional 10,000 shares in the last quarter. Rosalind Advisors Inc. increased its holdings in InspireMD by 0.6% in the second quarter. Rosalind Advisors Inc. now owns 2,289,099 shares of the company’s stock valued at $5,196,000 after buying an additional 14,109 shares in the last quarter. Soleus Capital Management L.P. increased its holdings in InspireMD by 99.5% in the second quarter. Soleus Capital Management L.P. now owns 1,886,207 shares of the company’s stock valued at $4,282,000 after buying an additional 940,831 shares in the last quarter. Finally, Courier Capital LLC increased its holdings in InspireMD by 83.3% in the third quarter. Courier Capital LLC now owns 55,000 shares of the company’s stock valued at $133,000 after buying an additional 25,000 shares in the last quarter. Hedge funds and other institutional investors own 44.78% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently weighed in on the stock. Loop Capital set a $5.00 price target on shares of InspireMD in a research report on Tuesday, February 24th. Lake Street Capital set a $4.00 price target on InspireMD in a research note on Monday. Piper Sandler reiterated an “overweight” rating and issued a $3.00 target price (down from $4.00) on shares of InspireMD in a research note on Tuesday. Finally, Maxim Group began coverage on shares of InspireMD in a research report on Monday, February 2nd. They set a “buy” rating and a $6.00 target price on the stock. Three research analysts have rated the stock with a Buy rating, According to MarketBeat, the stock has an average rating of “Buy” and an average target price of $4.50.

InspireMD Company Profile

InspireMD, Inc is a medical device company focused on developing next-generation stent technologies for cardiovascular and neurovascular interventions. The company’s core innovation lies in its MicroNet® mesh platform, a proprietary nanostructured covering designed to prevent embolic events during stent implantation. By integrating this fine mesh into traditional stent architectures, InspireMD aims to enhance safety and efficacy in the treatment of carotid artery disease and other vascular pathologies.

The company’s flagship offering, the CGuard® Embolic Prevention System (EPS), has received CE Mark approval and is commercially available in multiple international markets.